Oct 18th 2013 - Edison Investment Research today published a report on Arrowhead Research Corporation entitled "ARC-520 Found To Be Safe In Humans". In summary, the report says:
ARC-520’s attractive safety profile in healthy volunteers enables Arrowhead to proceed to a single dose, Phase IIa, pilot efficacy trial in HBV patients in Hong Kong, likely in Q413 or Q114, pending regulatory approval. A $60m (net) financing on back of this Phase I data provides sufficient cash to support ARC-520 until Phase IIb data as well as advance more new drug candidate(s) into human testing. We have updated our valuation to reflect the Phase I results and the impact of the new financing.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »